Email this article THE APPLICATION OF FLUCTUOPHORESIS FOR THE COMBINED TREATMENT OF MODERATE AND SEVERE CHRONIC GENERALIZED PERIODONTITIS
- Authors: P’yanzina A.V.1,2, Gerasimenko M.Y.1,2
-
Affiliations:
- ГБУЗ МО МОНИКИ им.М.Ф. Владимирского
- ГАУЗ Московская областная стоматологическая поликлиника
- Issue: Vol 12, No 1 (2013)
- Pages: 25-28
- Section: Articles
- URL: https://journals.rcsi.science/1681-3456/article/view/41345
- ID: 41345
Cite item
Full Text
Abstract
The present study included 220 patients aged from 35 to 75 years with the verified diagnosis of moderate and severe chronic generalized periodontitis. It was shown that fluctuophoresis had a positive influence on the clinical and rheographic characteristics and improved the parameters of laser Doppler flowmetry due to the beneficial effect on microcirculation. A course of mildronate fluctuophoresis promoted the improvement of myogenic regulation and nivalin fluctuophoresis normalized neurogenic regulation of the vascular tone. Actovegin fluctuophoresis proved to be sufficiently efficacious as a method for the treatment of the patients with both moderate and severe chronic generalized periodontitis in the absence of the marked prevalence of either myogenic or neurogenic regulation.
Full Text
##article.viewOnOriginalSite##About the authors
Anna Vladimirovna P’yanzina
ГБУЗ МО МОНИКИ им.М.Ф. Владимирского; ГАУЗ Московская областная стоматологическая поликлиника
Email: megakafedra@gmail.ru
Marina Yur’evna Gerasimenko
ГБУЗ МО МОНИКИ им.М.Ф. Владимирского; ГАУЗ Московская областная стоматологическая поликлиника
References
- Дмитриева Л.А. Пародонтит. М.: Медпресс-информ; 2007.
- Кречина Е.К. Мониторинг реактивности микрососудов пародонта с помощью лазерной допплеровской флоуметрии. В кн.: Применение лазерной допплеровской флуометрии в медицинской практике: Материалы 3-го Всероссийского симпозиума. М.; 2000: 133-4.
- Ушакова Г.Б. Применение флюктуирующих токов в комплексной терапии пародонтита: Дис.. канд. мед. наук. М.; 1990.
- Buchmayer F., Pleiner J., Elmlinger M.W., Lauer G., Nell G., Sitte H.H. Actovegin®: a biological drug for more than 5 decades. Wien. Med. Wochenschr. 2011; 161 (3-4): 80-8.
- Jaudzems K., Kuka J., Gutsaits A., Zinovjevs K., Kalvinsh I., Liepinsh E. et al. Inhibition of carnitine acetyltransferase by mildronate, a regulator of energy metabolism. J. Enzyme Inhib. Med. Chem. 2009; 24 (6): 1269-75.
- Osborn G.G., Saunders A.V. Current treatments for patients with Alzheimer disease. J. Am. Osteopath. Assoc. 2010; 110 (9, Suppl. 8): 16-26.
- Petersen P.E., Ogawa H. Strengthening the prevention of periodontal disease: the WHO approach. J. Periodontol. 2005; 76 (12): 2187-93.
- Pupure J., Isajevs S., Skapare E., Rumaks J., Svirskis S., Svirina D. et al. Neuroprotective properties of mildronate, a mitochondria-targeted small molecule. Neurosci. Lett. 2010; 470 (2): 100-5.
